Date	Event	Presentation	Speakers
February 20, 2012	Advances and Progress in Drug Design	Molecular obesity, potency and other addictions in medicinal chemistry	Mike Hann,
November 3, 2010	DIAâ€™s 8th Annual Canadian Meeting: â€œKeeping Canada on the Map: Fostering Innovation and Access to Drugs in Canadaâ€�	International Collaboration: An Industry Perspective	Neerja Goyal
April 28, 2010	HCV Drug Discovery	Boron and Non-Boron-Based HCV NS3/4 Protease InIhibitors: Discovery of a Novel Motif Possessing High Potency against PI-Resistant Mutants	Wieslaw Kazmierski
November 13, 2009	Globalization and standardization: Agreements-Budget-Regulation-Operations.	New Presentation	Dora MATHIASZ
November 3, 2009	ASAP-CHI Bio-Pharma Alliance Summit, Driving success with Effect ive Biotech/ Pharma Alliances	Launching the Alliance: What Big Pharma and Biotech Companies Need to Know	Bill Wilkison
November 2, 2009	Track 3: Fourth Annual Ion Channels as Therapeutic Targets	Title to be Announced	Derek J. Trezise
July 28, 2009	European Regulatory Affairs Summer School	Introduction to the eCTD and basic principles	Lillian Reilly
June 9, 2009	Cell and Tissue-Based Assays for HTS	Novel Assays and New Technologies	Kalpana Patel
		Table Six: Novel Assays, New Technologies and their Applications	Kalpana Patel
June 9, 2009	Third Annual Cardiotoxicity and Drug Safety	Use of Cardiac Troponin Measurements in Drug Development For the Detection of Cardiotoxicity	John K. Finkle
June 9, 2009	Translating Genomic Knowledge	Chairperson’s Remarks	Eric C Lai
		Panel Discussion – Successful Data Flow in Translation Discovery Research	Eric C Lai
		Integrating Pharmacogenetics Throughout the Pharma Value Chain	Daniel K. Burns
April 22, 2009	PI 3-Kinase Signaling in Disease (Z3)	PI 3-Kinase Pathway Modulation: Transition to the Clinic I	Richard F Wooster
April 21, 2009	3rd Annual Clinical Trials in Emerging Economies	Opening remarks from the chairperson	Allan Pamba
		Closing remarks from the chairperson	Allan Pamba
		Opening remarks from the chairperson	Allan Pamba
		Challenges and Lessons from a large Phase III clinical trial in Sub Saharan Africa	Allan Pamba
		Closing remarks from the chairperson	Allan Pamba
February 24, 2009	11th National Conference on Managing Legal Risks in Structuring & Conducting Clinical Trials	Workshop B: International Clinical Trials Boot Camp: The A to Z guide of essentials you need to know before going overseas	Elizabeth M Zechenter
February 23, 2009	Advances and Progress in Drug Design VIII	STRUCTURE BASED DRUG DESIGN WITH EMPHASIS ON GPCR MODELLING	Frank Blaney
February 8, 2009	CHEMISTRY IN CANCER RESEARCH: A Vital Partnership in Cancer Drug Discovery and Development	Session 5: Chemistry in Support of Lead Optimization/Case Histories I	Juan I Luengo
February 4, 2009	Adaptive Designs in Clinical Drug Development	Chairman's Opening Remarks	Alun Bedding
		SIMULATION IN ADAPTIVE TRIALS : Statistical modelling and its application to adaptive trials	Alun Bedding
February 3, 2009	Ramanbhai Foundation 4th International Symposium ---Ramanbhai Foundation 4th International Symposium--- “Advances in Cardiometabolic Research - Basic Science and Clinical Aspects”	“Application of large-scale genetics to support drug discovery and development in the cardio-metabolic area”	Vincent Mooser
January 26, 2009	Biomarker Assay Development	Development and Integration of Biomarkers into Clinically Useful Diagnostics	Anne Marie Martin
January 26, 2009	Translational Cancer Medicine	Development and Integration of Biomarkers into Clinically Useful Diagnostics	Anne Marie Martin
January 26, 2009	7th Annual Partnering with Central Labs	B1 : How to Reduce the Burden on Smaller Sponsor Clinical Team-The Cross Functional Approach	Karen Turner
January 5, 2009	High Content Analysis	Primary HCS for Immunomodulation	Carmel B Nanthakumar
December 2, 2008	4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development	1: The synthesis and design of PET radiotracers	Anthony Gee,
		2 : Opening remarks from the Chairperson	Phil Murphy,
		2 : PET for managing the gap between laboratory and man - A Drug Company Perspective	Anthony Gee,
		2 : Panel Debate: How translatable is preclinical and clinical imaging?	Phil Murphy,
		2 : Closing remarks from the chairperson and end of conference day one	Phil Murphy,
		2 : Opening remarks from the Chairperson	Phil Murphy,
		2 : Exploiting the benefits of DCE MRI (Dynamic Contrast Enhanced-MRI) in the assessment of antiangiogenic agents	Phil Murphy,
		2 : Closing remarks from the chairperson and end of conference	Phil Murphy,
December 2, 2008	2nd Annual Lead Discovery Summit 2008:-Compound Library Design, Synthesis & Acquisition	Ion channel modulators: a knowledge driven approach	Véronique Birault,
		Fragment based design and ligand efficiency – concepts and practice	Mike Hann,
		Experience of outsourcing to India and China	Duncan Judd,
		Biological fingerprints: Acceleration of hit identification and decision making in drug discovery	Wolfgang Jarolimek,
December 2, 2008	The 8th World Drug Discovery & Development Summit 2008	THE INDUSTRIALISATION OF CELLULAR SCREENING	Alan Wise
November 12, 2008	Third Annual Post-Approval Drug Safety Strategies: Best Practices to Mitigate Risks throughout the Product's Life Cycle	Genomics Role in Safety: Moving from Observation to Prediction & Leveraging New Tools and Thinking	Dan Burns
November 5, 2008	DIA's 6th Canadian Annual Meeting: Benefit and Risk Management: An Evolution in Progress	CANADIAN STEERING COMMITTEE	RAV KUMAR
		COMMUNICATION OF BENEFIT/RISK (SAFETY ISSUES)	DAVID , KRAKOVSKY
October 12, 2008	15th North American Regional Meeting - International Society for the Study of Xenobiotics	Drug Induced Vascular Injury	Brian R. Berridge
		Can Plasma Protein Binding Represent a Safety Issue for Drug Development? The Radafaxine Case	Paolo Rossato
October 8, 2008	Accelerating Proof Of Concept	Implementing New Approaches for Increasing Productivity of Drug Development	Dongzhou J. Liu
September 17, 2008	BACULOVIRUS TECHNOLOGY	Engineering A Better CHO Cell Host for Baculovirus Transduction	Patrick Condreay
March 30, 2008	Nuclear Receptors: Steroid Sisters	Drug Development	Dennis Sprecher
March 30, 2008	Nuclear Receptors: Orphan Brothers	Drug Development	Dennis Sprecher
March 25, 2008	Preclinical Development	Advances in Liver Toxicity Testing: What’s on the Horizon?	Holly L Jordan
March 25, 2008	TRENDS IN DRUG SAFETY	Advances in Liver Toxicity Testing: What’s on the Horizon?	Holly L Jordan
February 19, 2008	Screening Europe	Track B The Industrialisation of 1536 Well Format High Throughput Screening for Modulators of G Protein-Coupled Receptors	Stuart Baddeley
November 26, 2007	Obesity Drug Development World 2007	Targeting the Sodium Glucose Transporter II and developing selective inhibitors	Chari Smith
		Panel session: additional Q&A on SGLT2, GKA and GLP-1	Chari Smith
November 7, 2007	Bridging the Business Development/Alliance Management Interface Nov(7-8)	Leveraging the Power of a Strong Alliance - GlaxoSmithKline’s Center of Excellence for Drug Discovery (08:45-09:30)	Mark Strobeck
November 7, 2007	Stem Cells and Primary Cells in Drug Discovery	Welcome Remarks	Robert Ames
November 4, 2007	AACR Centennial Conference: Translational Cancer Medicine	Concurrent Session 1: Clinical Pharmacogenetics: Assessing Global Diversity	Eric C Lai
		Concurrent Session 3: Hereditary Cancers	Richard WOOSTER
October 17, 2007	Second Annual Ion Channels: An Emerging Target for Therapeutic Development Oct (17-18)	TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY (09:40-12:25)	Derek J. Trezise
		TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY: Novel Applications of Planar Array Electrophysiology in Ion Channel Drug Discovery (10:55-11:25)	Derek J. Trezise
		TARGETING PAIN MANAGEMENT: Chairperson’s Remarks (13:55-14:00)	Iain Chessell
		TARGETING PAIN MANAGEMENT (13:55-17:10)	Iain Chessell
		TARGETING PAIN MANAGEMENT: Novel and Translatable Mechanisms for Pain Treatment - Lessons From the P2X Receptor Family (14:00-14:30)	Iain Chessell
October 16, 2007	Second Annual Putting Theory into Practice: Adaptive Clinical Trial Designs (Oct 16-17	SESSION I: Setting the Stage for Adaptive Design Trials (14:00 - 14:30)	Judith A. Quinlan
		SESSION I: LAYING THE GROUND WORK FOR EARLY DECISION MAKING (13:45 - 19:00)	Judith A. Quinlan, Graeme E. Archer
		SESSION I: The Use of Bayesian Methods in Go/No-Go Decision Making (15:00 - 15:30)	Graeme E. Archer
		SESSION II: REGULATORY PERSPECTIVES AND LESSONS LEARNED FROM CONDUCTING STUDIES WITH ADAPTIVE TRIAL DESIGNS (08:30-11:15)	Judith A. Quinlan
		SESSION II: Co-Chairperson’s Opening Remarks (08:30-08:45)	Judith A. Quinlan
		CASE STUDIES (11:15-14:45)	Judith A. Quinlan
		CASE STUDY: Acute Migraine POC Using CRM - The Power of Team Work and a Can Do Attitude... Overcoming Logistical and Operational Hurdles (13:45-14:15)	Judith A. Quinlan
October 15, 2007	2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16)	BIOIMAGING FOR MONITORING RESPONSE TO THERAPY, DOSE SELECTION, ASSESSING MOLECULAR ACTIVITY AND RECEPTOR OCCUPANCY (08:00-13:30)	Robert A. Comley
		PET Receptor Occupancy - Accelerating Drug Development by Non-Invasive Measurement of Drug Action Early in the Development Pipeline (09:05-09:35)	Robert A. Comley
October 11, 2007	Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12)	SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30)	Dana E. Vanderwall
		SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Analysis of Biological Mechanism of Action, and Characterization of Profiles across the Progression Path (14:05-14:35)	Dana E. Vanderwall
October 2, 2007	IVT 's Lab Week	Stability Programs Regulatory Requirements \| Track B Building a Compliant Laboratory	Yin Jiang
		Type of Stability Studies \| Track B Building a Compliant Laboratory	Yin Jiang
		Batch Selection, Interval, and Storage Condition \| Track B Building a Compliant Laboratory	Yin Jiang
		Interactive Exercise \| Track B Building a Compliant Laboratory	Yin Jiang
		cGMP Regulations \| Track B Building a Compliant Laboratory	Yin Jiang
		State of Control \| Track B Building a Compliant Laboratory	Yin Jiang
		Lean Lab \| Track B Building a Compliant Laboratory	Yin Jiang
		Lab Operational Excellence \| Track B Building a Compliant Laboratory	Yin Jiang
		Interactive Exercise \| Track B Building a Compliant Laboratory	Yin Jiang
September 24, 2007	High-Content Analysis Europe: High content Cellular Assays for compound screening and Pahtway Analysis (Sep 24-26)	HCA for Mechanism-of-Action Studies: Use of the BD Pathway in CNS Drug Discovery to Determine Mechanisms of Compound Action in Primary Neuronal Cultures (16:00-16:30)	Claire Scott
		HCA for Mechanism-of-Action Studies (16:00-18:00)	Claire Scott
September 19, 2007	Baculovirus Technology (Sep 19-20)	Baculovirus: The Big Picture (08:30-10:35)	Michel Deschuyteneer
		Baculovirus - The Big Picture: FEATURED SPEAKER - Quality Assessment of GSK’s Cervical Cancer Candidate Vaccine Manufactured with the Baculovirus Expression Vector System (BEVS) (09:20-10:00)	Michel Deschuyteneer

BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.